Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

(2-Benzimidazolyl)acetonitrile derivative for the highly selective la-beling 5-formyluracil and its application in genome-wide mapping in tissues

ABSTRACT: (2-Benzimidazolyl)acetonitrile derivative for the highly selective la-beling 5-formyluracil and its application in genome-wide mapping in tissues

PROVIDER: PRJNA476499 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7352620_1.fastq.gz	Fastqsanger.gz
	SRR7352620_2.fastq.gz	Fastqsanger.gz
	SRR7352621_1.fastq.gz	Fastqsanger.gz
	SRR7352621_2.fastq.gz	Fastqsanger.gz
	SRR7352622_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

(2-Benzimidazolyl)acetonitrile derivative for the highly selective la-beling 5-formyluracil and its application in genome-wide mapping in tissues

Project description:Natural chemical modifications to 5-formyluracil (5fU) has been identified as an important oxidative nucleobase modification, is present in the genomes of many cell types. However, its distribution in genome is poorly understood. Herein, we present a selec-tive labeling and pull-down strategy termed fU-Seq for genome-wide 5fU profiling in mouse hippocampus and human thyroid carcinoma tissues. The mainly essence is using an azido modified (2-benzimidazolyl)acetonitrile derivative that selectively labels 5fU. Surprisingly, 5fU is highly enriched at intergenic and intron, and 5fU-rich regions are positively correlated with H3K27me3 and negatively correlated with H3K27ac, indicating that 5fU is associated with transcription. Collectively, the sequencing of 5fU allow comprehensive analysis of 5fU in genome and provide effective technology for mapping and paves the way for addressing biological and chemical questions regarding this nucleobase modification and for revealing its potential roles in epigenetics.

2018-11-28 | GSE115918 | GEO

LA-CB1, a novel Abemaciclib derivative induces apoptosis in breast cancer cells by inhibiting the CDK4/6-Cyclin D-Rb-E2F pathway path

Project description:Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) characterized by deletion of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (Her-2). It accounts for 10.0% to 20.8% of all pathological types of BC, has specific biological behavior and clinicopathological features, and has a worse prognosis than other types. TNBC usually has a high mortality and recurrence rate, and a poor prognosis after surgery, radiation, chemotherapy, and endocrine therapy. There are no conventional and effective treatments to control its progression. Therefore, we designed and developed a derivative based on Abemaciclib, named LA-CB1. To investigate the influence of LA-CB1 on biological function of TNBC. We use the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (MTT) to detect the viability of breast cancer cells. Evaluation of drug effects on cell migration and invasion by Transwell assays. Cell clone formation assay detects cell proliferation ability after drug addition. Subsequently, we determined the clinical significance and functional role of LA-CB1 through chick embryo experiments. Then, transcriptome sequencing technology (RNA-Seq) and bioinformatics methods were used to study the main pathway of LA-CB1 action on MDA-MB-231 cells. Western Blot assay verified the effect of LA-CB1 on the expression of CDK4/6-CyclinD1-Rb-E2F pathway protein. The compound LA-CB1 can inhibit the proliferation, colony formation, migration and invasion of TNBC cells. Effect of compound LA-CB1 on apoptosis and cell cycle detected by flow cytometry. The expression levels of CDK4, CDK6, CyclinD1, E2F1 and p-Rb proteins were positively correlated with LA-CB1 concentration. In summary, LA-CB1 showed a good anti-tumor cell proliferation effect, showing potential anti-TNBC drug candidate properties. This study provides new ideas and possibilities for TNBC treatment.

2024-10-11 | GSE276256 | GEO

Comparision of La-RNA-binding between wild type La and sumoylation deficient La mutant (K41/200R) in HEK293 cells.

Project description:We performed a RNA immunoprecipitations experiments using gfp-specific antibodies to precipitate gfp-tagged La proteins from from gfp-La wild type and sumoylation deficient La mutant (K41/200R) cells and found that specific mRNAs are preferentially enriched gfp-La wild type RIPs when compared to sumoylation deficient La mutant (K41/200R) RIPs.

2017-11-22 | GSE102842 | GEO

Highly Selective Brain-to-Gut Communication via Genetically-Defined Vagus Neurons

Project description:Highly Selective Brain-to-Gut Communication via Genetically-Defined Vagus Neurons

| PRJNA723274 | ENA

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies

| PRJNA391729 | ENA

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies I

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies I

| PRJNA391733 | ENA

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies IV

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies IV

| PRJNA391736 | ENA

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VI

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VI

| PRJNA391738 | ENA

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies III

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies III

| PRJNA391735 | ENA

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies V

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies V

| PRJNA391737 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data